ICU Medical, Inc. (ICUI) Tops Q4 EPS by 8c; Guides FY12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
Tweet
Share
E-mailGet Alerts ICUI Hot Sheet
Price: $163.27 +1.51%
Revenue Growth %: +2.8%
Financial Fact:
COST OF GOODS SOLD: 45.84M
Today's EPS Names:
SICP, MNSB, CFFI, More
Revenue Growth %: +2.8%
Financial Fact:
COST OF GOODS SOLD: 45.84M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
ICU Medical, Inc. (NASDAQ: ICUI) reported Q4 EPS of $0.70, $0.08 better than the analyst estimate of $0.62. Revenue for the quarter came in at $76.5 million versus the consensus estimate of $78.3 million.
ICU Medical, Inc. sees FY2012 EPS of $2.45-$2.70, versus the consensus of $2.67. ICU Medical, Inc. sees FY2012 revenue of $318-$330 million, versus the consensus of $325.69 million.
For earnings history and earnings-related data on ICU Medical, Inc. (ICUI) click here.
ICU Medical, Inc. sees FY2012 EPS of $2.45-$2.70, versus the consensus of $2.67. ICU Medical, Inc. sees FY2012 revenue of $318-$330 million, versus the consensus of $325.69 million.
For earnings history and earnings-related data on ICU Medical, Inc. (ICUI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Nebius shares fall on broader AI selloff, Piper Sandler target cut
- American Airlines (AAL) Tops Q3 EPS by 5c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
